Discovering next-generation dopamine transporter drugs with lower abuse potential.

Many traditional psychostimulants used to treat neuropsychiatric disorders by targeting the dopamine transporter (DAT) exhibit a high potential of abuse. This necessitates the development of next-generation drugs with improved safety. Discovering atypical DAT inhibitors represent a promising strategy that may be facilitated by integration of structural pharmacology and artificial intelligence.